NDA 050823 · B Braun
Ceftazidime In Dextrose Container
Ceftazidime · Injection
DiscontinuedLast checked: Nov 19, 2026Latest source record: Oct 20, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Jun 13, 2011
Approved uses
1
Original approval plus efficacy supplements
Registered trials
105
26 Phase 3, 18 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 13, 2011 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetterSummary Review
2 products under this application
- CEFTAZIDIME IN DEXTROSE CONTAINER · CEFTAZIDIME EQ 2GM BASE · INJECTABLE, INJECTION · Discontinued
- CEFTAZIDIME IN DEXTROSE CONTAINER · CEFTAZIDIME EQ 1GM BASE · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Ceftazidime" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe InfectionsPivotal-lookingNot yet recruiting
Southeast University, ChinaAcademic, hospital or other
NCT06939829 · 1,200 participants (planned) · Start May 1, 2025 · Primary completion Dec 31, 2027
Drug: treatment with CAZ-AVI · For: Patients With Critically Ill Infections
- A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial PneumoniaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01808092 · 969 participants · Start Apr 2013 · Primary completion Jan 2016
Drug: ceftazidim-avibactam (CAZ-AVI, experimental product); meropenem (active comparator) · For: Nosocomial Pneumonia (NP); Ventilator-associated Pneumonia (VAP)
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Florida, Argentina · 123 sites in all
- Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure InfectionsPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT00210899 · 828 participants · Start Sep 2005 · Primary completion Oct 2006
Drug: ceftobiprole medocaril; Vancomycin plus Ceftazidime · For: Skin Diseases, Infectious; Skin Diseases, Bacterial; Staphylococcal Skin Infections
- Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAIPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06633718 · 786 participants (planned) · Start Oct 31, 2024 · Primary completion May 30, 2027
Drug: Meropenem and Pralurbactam; Saline and 2 more · For: Intra-abdominal Infections
Sites: Hangzhou, China
- Ceftobiprole in Hospital Acquired PneumoniaPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT00210964 · 781 participants · Start Apr 2005 · Primary completion May 2007
Drug: ceftobiprole plus placebo; linezolid plus ceftazidime · For: Pneumonia
- A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe MelioidosisPivotal-lookingStatus unknown
University of OxfordAcademic, hospital or other
NCT00579956 · 750 participants (planned) · Start Dec 2007 · Primary completion Sep 2010
Drug: Meropenem; Ceftazidime · For: Melioidosis
Sites: Ubonratchathani, Thailand; Udon Thani, Thailand
- Single- Versus Multiple-dose Antimicrobial Prophylaxis for The Prevention of Infectious Complications Associated With Peroral Endoscopic Myotomy(POEM) for AchalasiaPivotal-lookingStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT03404739 · 666 participants (planned) · Start Oct 1, 2017 · Primary completion Dec 2018
Drug: Saline Solution; Ceftazidime · For: Esophageal Achalasia
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.
Wang Y, Sholeh M, Yang L, et al. · Antimicrob Resist Infect Control 2025 · Systematic Review, Meta-Analysis
- Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients.
Xie R, Rogers H, Chow JW, et al. · Antimicrob Agents Chemother 2025 · Clinical Trial, Phase III, Multicenter Study
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.
Torres A, Zhong N, Pachl J, et al. · Lancet Infect Dis 2018 · Clinical Trial, Phase III, Randomized Controlled Trial
- Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Scudeller L, Righi E, Chiamenti M, et al. · Int J Antimicrob Agents 2021 · Systematic Review, Network Meta-Analysis
- Antibiotic resistance rates in hypervirulent Klebsiella pneumoniae strains: A systematic review and meta-analysis.
Beig M, Aghamohammad S, Majidzadeh N, et al. · J Glob Antimicrob Resist 2024 · Meta-Analysis, Systematic Review
- Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis.
Wagenlehner F, Caballero VR, Maheshwari V, et al. · J Comp Eff Res 2025 · Systematic Review, Network Meta-Analysis
Sponsor: B Braun
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.